Management of fibrolamellar hepatocellular carcinoma

Chaudhari, Vikram; Khobragade, Krunal; Bhandare, Manish; Shrikhande, Shailesh V.

doi:10.21037/cco.2018.08.08

Cited by 45 publications

(57 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 Ablation and liver transplantation are effective in treating HCC, however, surgical resection remains the most important therapy, and is conducted in most patients with early stage HCC. [3][4][5] Despite the effectiveness of these treatments, recurrence and metastasis are still major problems for longterm survival in patients with HCC. [6][7][8] Chronic HBV infection is well-known to be associated with the development of cirrhosis and HCC, resulting in hepatic disease-related deaths.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma

et al. 2020

View full text Add to dashboard Cite

Objective: To investigate the prognostic value of change in liver stiffness following surgery, in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods: Patients with HBV-related HCC were included. Preoperative (baseline) liver stiffness and postoperative dynamic change in liver stiffness was evaluated. Results: Out of 158 patients in total, postoperative liver stiffness was increased in 98 patients and decreased in 60 patients compared with baseline values. Kaplan-Meier analysis revealed that patients with elevated liver stiffness had significantly worse overall survival outcomes than those with decreased liver stiffness. Similar trends were observed for diseases-free survival and recurrence outcomes. Multivariate analyses showed that Child-Turcotte-Pugh score (hazard ratio [HR] 1.209) and liver stiffness changes (HR 1.891) were independent factors associated with overall survival. Liver stiffness changes (HR 1.521) and a-fetoprotein level (HR 1.210) were found to be independent factors for disease-free survival in patients with HCC. Conclusion: Increased postoperative liver stiffness may be an independent risk factor of HCC prognosis. Patients with increased liver stiffness following surgery should undergo additional examinations during follow-up.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Hepatocellular carcinoma (HCC) is a highly aggressive and fast-growing malignancy with high lethality which lacks effective treatment [20,21]. There are many clinical trials of CAR-T cell therapy for HCC [22].…”

Section: Introductionmentioning

confidence: 99%

Co-expression of IL-7 and PH20 Promote anti-GPC3 CAR-T Tumor Suppressor Activity in Vivo and in Vitro

Liu

Wang

Jiang

et al. 2020

Preprint

View full text Add to dashboard Cite

While CAR-T therapy has successfully treated hematological malignancies, it has proved sub-optimal for solid tumors. The main limitation is the inability of CAR-T cells to infiltrate and then proliferate within tumors. In this study, we co-expressed IL-7 and PH20, a type of hyaluronidase, with CAR targeting GPC3 (G3CAR-7×20) to address these issues. We found (G3CAR-7×20) exhibited better proliferation in vivo and in vitro than G3CAR, reduced the level of apoptosis after stimulation by tumor cells, and maintained the memory phenotype of CAR-T cells. G3CAR-7×20 also increased the ability of CAR-T cells to infiltrate tumor tissue. G3CAR-7×20 may significantly enhance the efficacy of CAR-T cells in solid tumors.

show abstract

“…Fibrolamellar hepatocellular carcinoma (FL-HCC) is a primary liver tumor that usually presents at an advanced stage in early adolescents or adults at age 10-35 years with no underlying liver disease or cirrhosis [1] . FL-HCC often clinically manifests as abdominal fullness, pain, nausea, malaise, and weight loss; surgery is the only curative option at this time [2] .…”

Section: Introductionmentioning

confidence: 99%

Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report

Ljuboja

Weinstein

Ahmed

et al. 2020

Radiology Case Reports

View full text Add to dashboard Cite

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare primary liver tumor that typically presents at an advanced stage in early adolescents and adults with no underlying liver disease. Surgical resection is the first-line treatment, and patients who are not surgical candidates face limited treatment options with poor long-term outcomes. Herein we report the first documented, technically successful treatment of FL-HCC with extrahepatic spread using transarterial radioembolization (TARE) in a 16-year-old male patient with surgically unresectable disease. Subsequent imaging revealed tumor necrosis and a 20% reduction in size, and the patient survived 20 months post-treatment, a marked improvement relative to historical data in the literature. Further research should examine the potential role of yttrium-90 TARE in the treatment of FL-HCC patients with metastatic disease.

show abstract

Management of fibrolamellar hepatocellular carcinoma

Cited by 45 publications

References 0 publications

Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma

Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma

Co-expression of IL-7 and PH20 Promote anti-GPC3 CAR-T Tumor Suppressor Activity in Vivo and in Vitro

Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report

Contact Info

Product

Resources

About